US EditionAscletis's daily acne tablet set for China review after Phase III win - Pharmaceutical Technology
Summary by Pharmaceutical-technology.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
Ascletis's daily acne tablet set for China review after Phase III win
The Phase III trial, conducted by Chinese license partner Ascletis, produced strong results for denifanstat compared to potential rivals.The post Ascletis’s daily acne tablet set for China review after Phase III win appeared first on Clinical Trials Arena.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
